Ivermectin Mexico Peru India - Dr. John Campbell
Ivermectin and the odds of hospitalization due to COVID-19: evidence from a quasi-experimental analysis based on a public intervention in Mexico City
Case study: Policy intervention in Mexico City
Increase in COVID-19 cases and with critical levels of hospital saturation during December 2020
Mexico City Government decided to expand population-based health
Implementation of a prehospital home-care program
Combining early detection with antigen tests
Phone-based follow up for positive patients
Since 28 December, 2020, medical ivermectin kits have been provided to positive mild to moderate symptomatic patients
Dyspnea, chest pain or cyanosis, referred to a hospital
Ivermectin, four 6mg tablets, two pills for two days
After one month, 83,000 medical kits delivered
Detailed data was collected on the evolution of patient illnesses
Quasi-experimental evaluation of the effects of the medical kits on
Kit receivers and non-kit receivers
Matched observations, adjusting by age, sex, COVID severity, and comorbidities
Controls, N = 156,468 patients with COVID-19 infection before implementing the ivermectin program
Experimental group, n = 77,381 after the implementation
Outcome variable: whether or not the person was hospitalized
Negative and significant effect of the ivermectin-based medical kit on
the probability of hospitalization
Effect ranges from 50% to 76%
Difference in hospitalization odds between treated and untreated patients, statistically significant in all cases
As expected, the effect of the medical kits is higher and stronger among males, in older patients, and in cases without severe symptoms
Discussion and limitations
we found that the medical kit given en masse to patients who’d tested positive in Mexico City had a negative, significant, and robust effect on their odds of being hospitalized.
Independently of the medical telephone follow, level of hospital occupancy, specific period of time
Similar trend, Perú (Chamie-Quintero Et Al, 2021).
Principal mechanisms, reduction of viral load, in the patients that take ivermectin in early stages of the disease
Chamie-Quintero Et Al, 2021, Peru
25 states of Peru
Grouped by extent of IVM distributions
Maximal, medium, minimal
Reductions in excess deaths (30 days after peak deaths)
Reduction of excess deaths is correlated with extent of IVM distribution by state p less than 0.002
This strongly suggests that IVM treatments can likewise effectively complement immunizations to help eradicate COVID-19.
The indicated biological mechanism of IVM,
competitive binding with SARS-CoV-2 spike protein,
is likely non-epitope specific,
possibly yielding full efficacy against emerging viral mutant strains.
Uttar Pradesh government, first to have introduced a large-scale “prophylactic and therapeutic” use of Ivermectin
Helped the state to maintain a lower fatality and positivity rate as compared to other states
Health Department introduced Ivermectin as prophylaxis for close contacts of Covid patients, August 6, 2020
Agra, Dr Anshul Pareek and State Surveillance Officer Vikssendu Agrawal
Administered Ivermectin to all RRT team members in Agra
None of them developed Covid-19
Despite being in daily contact
Despite being the state with the largest population base and a high population density, we have maintained a relatively low positivity rate and cases per million of population
Lower positivity and fatality rates may be attributed to the large-scale use of Ivermectin use UP
|Sensitivity||Normal - Content that is suitable for ages 16 and over|
2 days, 19 hours ago
Warning - This video exceeds your sensitivity preference!
To dismiss this warning and continue to watch the video please click on the button below.
Note - Autoplay has been disabled for this video.
This advertisement has been selected by the BitChute platform.
By purchasing and/or using the linked product you are helping to cover the costs of running BitChute. Without the support of the community this platform will cease to exist.
Registered users can opt-out of receiving advertising via the Interface tab on their Settings page.
To help support BitChute or find out more about our creator monetization policy: